The role of adenosine A1 receptor agonist in adenosine augmentation therapy for patients with refractory epilepsy in Sturge-Weber syndrome: An in vitro electrophysiological study.

CONCLUSION: Our results supported the potential of AATs using A1R agonist to be a novel therapy for reducing life burden from patients with refractory epilepsy in SWS, with application to epileptic generation region but not propagation region. PMID: 32208337 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/32208337?dopt=Abstract

Source: Epilepsy and Behaviour - March 20, 2020 Category: Neurology Authors: Wang X, Cao L, Guan Y, He Q, He X, Zhou J, Li T, Luan G Tags: Epilepsy Behav Source Type: research